Podcasts about medidata solutions

On this week's episode, Lisa Moneymaker (SVP, Head of Strategic Customer Engagement, Medidata Solutions) and Adam Aten (Legislative & Regulatory Policy Lead, Verily) join the podcast to discuss how the clinical research industry must use insights from the past to better prepare our AI models and other technologies to meet the needs of patients in the present and future. They dive deeper into the role that collaboration between technologists and clinical scientists can play in helping to reduce bias in our AI models, what legislators and regulators should be keeping top of mind as they write new rules of the road for AI and ML, and ACRO's ongoing efforts to promote the responsible use of AI in clinical research.

Thank you for listening. Send us a text message. In this episode of Intentionally Overheard, Dave Bjork, "The Research Evangelist" shares his outlook on life, his lung cancer journey, and how living a life of purpose has inspired him to live his best life by helping others.     Dave Bjork is a lung cancer survivor, patient advocate and research evangelist with more than 25 years of progressive experience in community-building, nonprofit fundraising, and research advocacy.  Dave is host of the Research Evangelist Podcast where he interviews leaders in lung cancer research and care, and the Dinner with Dave Podcast where he shares lung cancer stories of inspiration and courage from patients and care partners. In addition, he is an advisor to Medidata Solutions where he serves on the Patient Insights Board team to bring the patient voice to the clinical trial experience. Previously Dave spent 8 years leading nonprofit fundraising and advocacy teams.Dave has made it his life mission to connect patients, biopharma companies, academic institutions, and other key influencers to forge strong partnerships to focus on cancer research and care. He proudly serves on the Advisory Board of the Cancer Epigenetics Institute at Fox Chase Cancer Center. Dave earned a BS in Economics and Finance from the Wharton School at the University of Pennsylvania.Twitter @bjork5 https://www.linkedin.com/in/davebjork/ https://www.instagram.com/theresearchevangelistpodcast/?hl=en https://www.facebook.com/david.bjork.71Support the show

Input from research sites is essential for developing clinical technologies that are practical, efficient, user-friendly, and aligned with the real-world needs and challenges of trials. Understanding this need, Medidata Solutions hosted an interactive Site Tech Board through SCRS to learn how to improve their technology and processes directly from sites. Tune in as Robin Douglas, Vice President of Research Site Engagement at Medidata, highlights how the organization is creating a better experience for sites and patients through this feedback.

2024-07-19 Hosts Jane Myles and Angela Radcliffe were joined by Alicia C. Staley from Medidata Solutions for a fabulous conversation about her whitepaper on Medidata's Patient Centricity by Design (PCbD) process and the work they are doing to accommodate the perspectives and preferences of patients and caregivers.You can join TGIF-DTRA Sessions live on LinkedIn Live Audio on Friday's at 12:00 PM ET by checking out our LinkedIn. Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.

Billy Martin is a Senior Director for Strategic Programs and Leadership Development at Medidata Solutions as well as the creator of FLIP'D Coaching for Performance. The FLIP'D framework has been experienced by over 4000 corporate leaders around the world since it's inception. Billy spent 10 years at Salesforce.com before coming to Medidata.  He has a Masters Degree in Sports Medicine and an MBA degree in Technology Management. Billy co-founded several technology companies on his journey toward leadership development. Billy has six Amazon.com Top Sellers on Sports Officiating and Business he loves teaching other aspiring referees / umpires — and does so for high school soccer and basketball, as well as collegiate softball.  Tony Severino is a business leader, leadership skill developer, master facilitator and coach. He draws on the experience as a business leader and coach who led organizations at companies like Xerox, Salesforce and his own company. He spent his time at Salesforce as director of sales leader enablement and program manager where Tony's team created and delivered the highest ranked, and award winning global leadership programs in the company's history. Tony has personally facilitated leader training for thousands of leaders at Salesforce. Now at FLIP'D, Tony and Billy work with companies to develop their leaders at all levels within the organization using proven, engaging workshop content and coaching tools. To learn more about Billy, you can go to his Linkedin profile: @crmbilly To learn more about Tony, you can go to his Linkedin profile: @arsevr or You can go to their website: flipdcoaching.com --- Support this podcast: https://podcasters.spotify.com/pod/show/lyndsay-dowd/support

In this episode, we explore the transition from EHR (Electronic Health Records) to EDC (Electronic Data Capture) and its implications for healthcare professionals and patients alike. Dan Braga, Vice President of Product Management and Digital Health Solutions at Medidata Solutions, shares how patients, healthcare providers, researchers, and the healthcare industry as a whole gain from the seamless integration of these technologies. Learn about the roadblocks faced by the industry and why this groundbreaking transformation has taken time to reach its full potential.

Wendy Lurrie is most recently the CMO at Sinequa and high-level marketing leader at organizations like Medidata Solutions and well recognized marketing agencies. She's an expert across the full spectrum of marketing disciplines with broad and deep experience in brand, direct, CRM , digital marketing and integrated marketing.Learn more about Sinequa:http://www.sinequa.com/Connect with Wendy Lurrie on LinkedIn: https://www.linkedin.com/in/wendy-lurrie-392b053/Connect with the host, Connor Dube, on LinkedIn`https://www.linkedin.com/in/socialsellingexpert/Brought to you by the B2B content marketing experts at www.ProvenContent.comGet access to free content marketing courses, no email opt in required, at www.ProvenContent.com/Free

Wayne Walker is Senior Vice President, Product for Rave Platform Technology (including Rave EDC, Rave RTSM, Rave Imaging, Rave Coder, and Rave Safety Gateway) at Medidata. His responsibilities include the strategy, development, and delivery of these products across all Research & Development disciplines. Before joining Medidata, Wayne spent 12 years overseeing Product Management for clinical technology used by Data Management and Biometrics at PRA Health Sciences. This involved oversight of Platform as a Service, Software as a Service, on-premise deployed environments, and in-house developed solutions This week we discuss the vendor/site relationships, why there is a proliferation of disparate systems, the potential of direct to EDC data entry and so much more.

Madalina Tanasie joins us to share her unique leadership journey as she transitioned from eng to operations, then back to her current technical role as CTO @ Collibra. We also cover strategies to improve engineering efficiency within your organization, factors to consider when scaling eng teams, maximizing your ROI when it comes to R&D, dispelling concerns when implementing culture changes, frameworks for scaling up, and more.ABOUT MADALINA TANASIEMadalina Tanasie is the Chief Technology Officer and an Executive Committee member at Collibra, where she oversees and leads the Software Engineering, Architecture, Production Engineering, Test Engineering, and Security activities.Madalina has over 18 years of software engineering leadership experience and her expertise is in service-oriented architecture, cloud-native distributed systems, and product operations with a focus on engineering practices, scale, and operational excellence. Prior to joining Collibra in 2020, she was the Engineering VP for Medidata Solutions' Unified Platform Organization, an organization she built from the ground up and led since 2010.She has been recognized as one of the Top 25 Software CTOs of 2023 by The Software Report.Additionally, she is a proud sponsor of Collibra's Women in Technology, and an active member of CHIEF, a network focused on connecting and supporting women executive leaders. Ms. Tanasie earned her BS and Master's in Computer Science at Polytechnics University of Bucharest."The reality is that they need process and structure to eliminate the noise and to create a space for solving really, really deep challenging problems. They actually want the process for the part that is mundane and boring and disruptive. So as they discuss about what's making their life harder than it needs to be, we are coming back to a lack of process, a lack of uniformity, a lack of clear communication channels between themselves or between other departments.”- Madalina Tanasie   Check out QA Wolf!Looking for a way to increase end-to-end test coverage, speed up your release cycles and reduce bugs from shipping to production? QA Wolf will build, run and maintain your test suite - so that you don't have to.QA Wolf gets you to 80% automated end-to-end test coverage in 4 months - and keeps you there – So your team can stay focused on shipping!Learn more & schedule a 30 min demo at qawolf.com/elcLooking for ways to support the show?Send a link to the show to your marketing team! https://sfelc.com/podcastsIf your company is looking to gain exposure to thousands of engineering leaders and key decision-makers, we have sponsorship opportunities available.To explore sponsor opportunities, email us at hello@sfelc.comSHOW NOTES:Madalina's unexpected career journey, beginning @ Medidata (2:13)How Madalina transitioned from engineering into operations @ Collibra (4:57)Qualities that make Collibra's culture stand out (5:46)What opportunities stood out when Madalina was evaluating the Collibra role (7:35)Four considerations to keep in mind when scaling eng teams (9:07)The Spotify model vs. Agile model & what worked for Collibra (15:19)Challenges to adopting new management models (19:18)Strategies for navigating people's expectations (20:58)Insights gained from Madalina's “listening tour” (23:20)Frameworks for addressing concerns around culture while scaling (25:04)Madalina's perspectives on improving engineering efficiency (26:51)The right balance between cost of ownership and R&D (30:07)Collibra's new product introduction process & its impact on R&D (31:28)Questions to help guide teams throughout the new framework (33:11)Rapid fire questions (34:22)This episode wouldn't have been possible without the help of our incredible production team:Patrick Gallagher - Producer & Co-HostJerry Li - Co-HostNoah Olberding - Associate Producer, Audio & Video Editor https://www.linkedin.com/in/noah-olberding/Dan Overheim - Audio Engineer, Dan's also an avid 3D printer - https://www.bnd3d.com/Ellie Coggins Angus - Copywriter, Check out her other work at https://elliecoggins.com/about/

Matthew Flotard, Global Finance Head of Strategic Sales at Celonis, joins Justin Lane, VP of Professional Services at Forma.ai, on this episode of The Sales Compensation Show. They dive into a multitude of topics such as best sales practices for roll out and communication in the field; the decision of Medidata Solutions to move from Total Contract Value (TCV) to Annual Contract Value (ACV) bookings; and how Matthew handles contract cancellations, managing the effects, meeting targets, etc.

Clinical trials are essential to progress in medicine, but racial and ethnic minorities are frequently underrepresented in such studies. In this ASCO Education podcast episode, we will examine this issue with Dr. Carol Brown, gynecologic cancer surgeon and Chief Health Equity Officer at Memorial Sloan Kettering Cancer Center, Dr. Ana Maria Lopez, Professor and Vice Chair of Medical Oncology at Sidney Kimmel Medical College and former Chair of ASCO's Health Equity Committee and Mr. Ted Bebi, Innovation Manager at Medidata Solutions. They discuss how diversification of clinical trials contributes to health equity (4:03), barriers to participating in clinical trials (14:37), and what clinicians and trial sponsors can do to improve participant diversity in clinical trials (20:25).  Speaker Disclosures Dr. Carol Brown – None Ted Bebi: Employment – Medidata (a Dassault Systèmes company); Stock and Other Ownership Interest – Pfizer, Eli Lily, Abbvie, Merck, BMY        Dr. Ana Lopez - None Resources ASCO-ACCC Initiative to Increase Racial & Ethnic Diversity in Clinical Trials Journal Article: Increasing racial and ethnic diversity in cancer clinical trials Journal Article: Representation of minorities and women in oncology clinical trials Podcast: Impact of Implicit Racial Bias on Oncology Patient Care and Outcomes ASCO-ACCC JustASK Training Program If you liked this episode, please follow the show. To explore other educational content, including courses, visit education.asco.org. Contact us at education@asco.org. TRANSCRIPT Dr. Carol Brown: Welcome to the ASCO Education podcast. I'm Dr. Carol Brown, a gynecologic cancer surgeon and the Chief Health Equity Officer at Memorial Sloan Kettering Cancer Center. Our guests and I will be exploring the problems and solutions with regards to racial disparities in clinical trials.   A necessary element for conducting clinical trials is, obviously, the enrollees or participants. Racial and ethnic diverse groups are frequently underrepresented in clinical trials, despite having a disproportionate burden for certain cancers. In addition, there is increasing evidence that a person's individual genetic makeup may determine the level of toxicity or efficacy of a new cancer drug specifically. Therefore, when we don't have enough diversity in our cancer clinical trials, it can really undermine the generalizability of our results. And so, to address this gap, in its recent updated guidance to industry, the US Food and Drug Administration stated that enrollment in clinical trials should reflect the diversity of the population who ultimately use a treatment.   In 2022, ASCO and the Association of Community Cancer Centers issued a joint statement recommending that anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving equity, diversity, and inclusion.   Joining me to discuss this important topic today is Dr. Ana Maria Lopez, who's the Professor and Vice Chair of Medical Oncology at the Sidney Kimmel Medical College. And she's the former Chair of ASCO's Health Equity Committee. Our second guest is Mr. Ted Bebi, Innovation Manager at Medidata Solutions. His research explores underrepresentation of black patients at clinical trials and how diversity impacts clinical trials.  Participant disclosures for this episode are listed on the podcast page.  So why should we care about improving diversity in clinical trials? Dr. Lopez? Dr. Ana Maria Lopez: We are clinicians. We are wanting to take care of our patients as best as possible, and we can only do that if our studies include everyone. An example that I often think about is the concept of airbags began in 1953, and in 2008, the National Highway Traffic Safety Administration came out and said, “You know what? We should be testing airbags on small female crash test dummies because otherwise, we don't know that these airbags will be safe.” And in fact, there were data that the airbags that existed put women and children at a much higher risk for injury or death. So, we want to be ahead of that curve, and we want to allow the best possible treatment. Dr. Carol Brown: So, Mr. Bebi, what would you say about how we could improve diversity in clinical trials? Ted Bebi: So I really like the example of the airbags that Dr. Lopez brought up because it makes it clear when building a product it's important to test the product in a representative sample of the population that will ultimately end up using it. It's the same with products like medications. If you want an efficacious drug, you should test it in the appropriate population. It's what constitutes good science. Additionally, adequate diversity in clinical trials is also important because it's ultimately an issue of health equity and providing fair access. Dr. Carol Brown: Could you kind of go on from there and talk about, specifically, how does diversifying the group of people that participate in clinical trials actually translate into increasing health equity?  Ted Bebi: Well, participating in a clinical trial is a form of receiving health care. Often, we are talking about patients for which a clinical trial might be their last resort. And even if not, participating in a clinical trial means gaining early access to potentially life-changing drugs that could become the new industry standard and doing so at no cost. So, you're receiving care and follow-up from some of the best specialists in the field. So having fair access to this opportunity for all patients is definitely a health equity issue. Dr. Carol Brown: Great. Dr. Lopez, how would you answer that question about how does diversifying clinical trials contribute to health equity? Dr. Ana Maria Lopez: Yeah, no, I think I agree with everything that Mr. Bebi said. In addition, I think we have to remember that diversity is more than race. Race is truly a social construct. We need to think about gender. We need to think about age, the whole lifespan, and people are living longer. How we metabolize medications at different time points in our life may vary. So, lots of different factors that we can consider when we think of diversity. But the gold standard is really: Are folks getting the best outcome possible? And as long as that metric is not being reached, we need to be thinking of how can we facilitate that. Dr. Carol Brown: So, Dr. Lopez, you brought up this concept that health equity is really the best outcome possible. Could you comment a little bit about how do we know, particularly in cancer, what is the best outcome possible? So how do we determine what the reference is for that, so we can figure out whether our patients are actually getting health equity? Dr. Ana Maria Lopez: Sure. So, we use different time points. We can look at relapse rates, survival rates, and of course, part of that may be comorbidities. Certain comorbidities that people have may impact their cancer treatment outcomes. So, it is complex, but it is important for us to take a look contextually at what the patient's risk is and what the patient's outcome would be. Dr. Carol Brown: We can kind of all agree that when we're talking about equity, it's getting the best outcome for everybody, no matter what they're bringing to it. And I really like your comment, Dr. Lopez, about race being not only the only factor but remembering that it is a social construct. If you could add to that, Mr. Bebi. Ted Bebi: We're talking a lot about diversity in clinical trials in terms of race and ethnicity, and that is something that is ultimately very important. But we're talking about diversity in all sorts of aspects. We're talking about diversity with age. We're talking about diversity with sex, with socioeconomic aspects because we often use race as a proxy for other things that might be going on in patients' lives. And we need to consider all of this part of diversity in clinical trials because once the drug is out in the market, it will be an intersection of potentially all of those identities and many things going on in their life that might affect how they respond. So, when we're thinking about race as a diversity point, we might be using it as a proxy for a specific type of individual, a specific patient journey that we want to make sure to include. It's not necessarily that race is the end-all, be-all measure of diversity; it's that we want to capture the true patient experience for that disease. Dr. Ana Maria Lopez: What I think is also really interesting is how we collect the data. And some of what the last couple of years have taught us is that folks may not trust our healthcare systems, and so folks may not be willing to say, ‘I am X, Y, or Z,' which certainly puts us a little bit in the void. So how important it is for us as clinicians, as researchers, to be part of creating an environment where patients can feel that ‘Yes, I can trust and I can share, and I can say, this is who I am,' because that could impact clinical care. Dr. Carol Brown: So, acknowledging that race is a social construct and that it really is used as a surrogate for other social determinants of health and other factors that affect health, and again, really acknowledging what you said, Dr. Lopez, that even asking people to identify their race is extremely problematic. But given what we do know and what our experience has been in the clinical trial world, first, Mr. Bebi, could you comment about what has been your experience and your research with the current state of participation by diverse racial and ethnic groups in clinical trials in the United States? What have you found in your research?  Ted Bebi: Recently, at Metidata, we published a paper where we looked at the state of black participation in clinical trials. We found the level at which you look at the data really matters. For example, when we looked at racial diversity across all US trials, black representation actually matched the proportion of black people represented in the 2020 US National Census, which is about 14%. But looking deeper, there were actually huge differences by therapeutic and disease area. And specifically, we saw that in oncology, black participation was only at around 8.5%, so far below the representation of black people in the United States.   Another interesting story is that when we were looking at the central nervous system therapeutic area, overall, we saw a pretty high rate of black participation at around 20%. But when we looked at one of the largest central nervous system indications, Alzheimer's, we saw only 5% black participation, so much, much lower. What we discovered is that within this therapeutic area, there were actually a lot of psychiatric trials that were driving the rate up. So, the main takeaway from this research is that you cannot take a general level of diversity as adequate for all diseases. You really have to zoom in on the specific indication to understand what constitutes good diversity or representative diversity for that disease.  Dr. Carol Brown: I'd like to ask both of you what do you think about that - what the bar should be. Because Mr. Bebi, you mentioned using the census distribution of races in the population, but I think a lot of us in the cancer field feel like that maybe isn't the right bar. Maybe the bar should really be what is the cancer burden distributed according to self-identified race, ethnicity, or other categories. And when you look at that, I think you find some different statistics. So, Dr. Lopez, could you comment about what your work has shown you about the current state of representation of diverse people affected by cancer in cancer clinical trials, and maybe get a little bit more into what you were saying earlier about the definition of race and the challenge of determining race, etc. Dr. Ana Maria Lopez: We really need to look closely at the data, and that looking at therapeutic trials and at specific populations can be really important. Now, we're a big country, so there can be - what is the catchment area that you serve? And in that catchment area, what are the cancers you're treating, and in which populations are at greatest risk? But right, sometimes it may not be - let's say the population is 10%x, but if that population is at higher risk for a certain disease, to really get granular about the understanding, I need to recruit more people that are from that greater-risk population. So that's where I think it's so important to know the population, to have connections with the community. And actually, the community can say, “Hey, this is what you may want to be studying because this is what impacts us.” Ted Bebi: If I can speak on the research side as well, the best way to ensure representative diversity is to have a very solid understanding of the natural prevalence of a disease. We need to be able to understand what the risk populations are and, even further, what does the mortality look like? Are there differences in how different patients are experiencing the disease further on, not just how they're getting the disease and how often they're getting the disease? So it needs to look different for every single indication. And even with the oncology, for example, the two largest indications in clinical trials for oncology, lung cancer and breast cancer, they also look slightly different. With lung cancer, and our research showing at 8% black participation and breast cancer being a little bit higher at around 11%. So, we always need to take into consideration that incidents include prevalence, include mortality. And yes, the golden standard should be can we build a clinical trial that reflects the actual representative diversity of the disease in the real world? That is what we're striving for. Dr. Carol Brown: I would agree with that. I would also add, though, that there may be some specific cancers for which you want to have an even greater representation of a particular group because it might be directly related to the question you're trying to answer. So, for example, you mentioned breast cancer, so I think most of the audience is probably aware that young women who self-identify as black tend to have a higher mortality from breast cancer. And this is believed to be because they are more likely to get triple-negative breast cancer. And so one of the strategies we've looked at at our cancer center is for trials specifically for triple-negative breast cancer, trying to overrepresent women who self-identify as black or have African ancestry in those trials because we're specifically trying to make sure that we do something to narrow that gap in survival from breast cancer that they experience. So, I think that, as you all mentioned, I think what we can take from this is it's really important to look closely that there are different layers and subtleties that we have to take into account.  So, I think we've clearly established that there is underrepresentation of diverse groups. But let's talk about why. So why do we think that different self-identified races and ethnicities or age groups or socioeconomic status background people are underrepresented in clinical trials? What are some of the reasons in your experience for this, Dr. Lopez? Is it funding outreach? What are the main barriers that you've experienced in terms of getting diverse populations to participate in clinical trials? Dr. Ana Maria Lopez: Maybe all of the above. But one of the things, and one of the things that we're working on, is when a person comes in and you have the trauma of the diagnosis. And they're offered a study, and there may be suspicion of the health care system, that may not be the best time to really talk and educate around a clinical trial. So, if people receive the education, learn about clinical trials before that acute event, then they can come in more prepared. So, one is just the concepts of randomization, double blind in the setting where there may be distrust of the healthcare system may be difficult. Also, some of the clinical trials, and I'm sure everyone has studies where the person needs to be at the clinic for about 12 hours getting blood draws. And people have other responsibilities, and they may not have the support mechanisms for transportation, for childcare, for elder care. And if you're taking two to three buses and, you know, here I am in Center City, Philadelphia, and you need to take two to three buses to get home at 07:00, that could be a deterrent to getting on a clinical trial.   So, there are lots of clinical factors, social factors, experience with the studies, and also how we design the studies. Can we design studies so that we are more inclusive in the criteria? So, I think lots of questions, and then certainly there are clinician factors. There could be bias that we all have that maybe we don't offer studies to certain people, so something for us to be very introspective about as well. Dr. Carol Brown: So, Mr. Bebi, could you comment specifically on, with the research that you've done, are there some barriers on the side of the sponsors of the trials or in terms of industry that you found and that you found in your work at Medidata, maybe really affecting the ability of diverse people to participate in clinical trials? Ted Bebi: Dr. Lopez did a really good job at presenting what we consider patient-level barriers, such as mistrust in the healthcare system. Logistical issues such as taking time off from work, transportation, or feeling that the investigators running the trials don't fully represent the patient. But the industry-level barriers are just as important. A lot of companies are making decisions on what good diversity should look like and where they can find more diverse patients based on incomplete data sources such as disconnected external data, or they might be limited to data from the companies.  Dr. Carol Brown: Great. So, Dr. Lopez, what do you think individual physicians can do, or individual investigators can do to improve the diversity of representation in cancer clinical trials? Dr. Ana Maria Lopez: Certainly, being circumspect, being aware of our own biases, our own approaches. But as a health system, I think we need to think about: How can we make it easy to enroll people into trials? So are there ways, if this is, for example, a study for people at this stage of cancer, that all of those patients could be screened in the electronic record? Let's have our electronic tools work for us so that we identify patients that are meeting the study criteria and then connecting the patients, the study, and the investigators together. So, this way, by having our systems identify potential participants, there's a less chance of there being that personal bias. The research team can come to the doctor, to the oncologist, let's say, and say these are folks that are eligible. What do you think? So, in a way, setting up systems to help with the recruitment would be very helpful. Dr. Carol Brown: Mr. Bebi, can you comment from the standpoint of specifically– because you focus on this– the importance of data, the data, how to capture the data about race or ethnicity or whatever the demographic diversity variable is, what can individual investigators do to really address the challenges around collecting this data and sharing it? Ted Bebi: Often, race and ethnicity data is not even captured at all. So, if we want to understand this issue better and improve upon it, we need better data inputs in order to produce this large-scale research that will help us ultimately advance the issue and not just rely on anecdotal information. Dr. Carol Brown: Are there any technologies or things that you came across in your specific work that can help with this ability to capture this type of data and to share it? Ted Bebi: I think it has more to do with the awareness and the clinician relationship with the patient. And I also think it has to do with sponsors and the way that they design the trial, to begin with, whether or not the race and ethnicity entry is something that they're asking in their electronic health forms. Because if that is not included in the clinical trial, to begin with, then there won't be any incentive to capture that information. Dr. Carol Brown: Dr. Lopez, do you have any specific tips that you would recommend to clinicians who want to improve recruitment of underrepresented groups in their clinical trials? Dr. Ana Maria Lopez: I think one thing that's really important is to be able to have the time. Now, that may not mean that it's all the clinicians' time. It may mean that you have a research coordinator. It may mean that you have a research nurse. It may mean that you give the patient a video that explains the study that they can take home. There can be different ways. Something that I often ask a patient is, “How do you make decisions?” People tell me, “You know, I always go over this with my wife,” let's say, or, “I always discuss this in our family, and then we come to a conclusion.” Because that really helps me to think about how should I best deliver the information so that the patient can really feel I made a good decision and I made a value-congruent decision. So, I think time is critical and to set up our patient experience to really facilitate that type of experience for the patient.  Also, as a reference, I would urge people to take a look at the recent recommendations put out by ASCO and ACCC that talk specifically about increasing racial and ethnic diversity in cancer clinical trials. So, there are lots more strategies, a lot more ideas, and ways to really support clinicians and researchers. Dr. Carol Brown: Mr. Bebi, do you have any specific tips, particularly for trial sponsors, about how they can improve diversity in their clinical trials? Ted Bebi: In terms of companies and sponsors, what they can do if they want to improve diversity in their trials is they need to find and include the right sites that serve the populations that they are looking for. We published research that shows that there is high variability of diverse recruitment based on which sites you are looking at, with some sites providing the highest concentration of diverse patients. So, if diversity is not woven into trial design off the bat and you're not selecting the right sites, you run the risk of not reaching these populations. Companies also need to be willing to put in work to educate and develop sites into clinical trial sites. A clinical trial site is about building trust and relationships and knowing how to be culturally adept at talking to diverse communities.   Dr. Carol Brown: Great. Thank you so much. Well, I want to thank both of you, Dr. Lopez and Mr. Bebi, for a lively discussion on this ASCO Education podcast about diversity in clinical trials.   The ASCO Podcast is where we explore topics ranging from implementing new cancer treatments and improving patient care to oncologist well-being and professional development. If you have an idea for a topic or a guest you'd like to see on the ASCO Education Podcast, please email us at education@asco.org. To stay up to date with the latest episodes and explore other educational content, please visit education.asco.org.  Speaker Disclosures Dr. Carol Brown – None Ted Bebi: Employment – Medidata (a Dassault Systèmes company); Stock and Other Ownership Interest – Pfizer, Eli Lily, Abbvie, Merck, BMY       Dr. Ana Lopez – None The purpose of this Podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this Podcast express their own opinions, experience, and conclusions. Guest statements on the Podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

What does it take to create leadership training programs that result in real behavior change? Billy Martin has the answer because he's done this successfully with sales leaders in two global companies—Salesforce and Dassault Systems. He describes all the elements built into their process, including teaching leaders how to ask powerful questions that draw out the native genius of their team members.Billy is Senior Director of Strategic Programs and Leadership at Medidata Solutions, a Dassault Systems Company. He's passionate about leading teams of professionals that create programs for onboarding new sales leaders and B2B sales reps around the world. His team builds and delivers various leadership business simulations, training programs, guided coaching activities and skill assessments --- all designed to scale globally across the leadership community.  Billy is the co-author of One Thing: Focus on Sales Leadership: Insight from Top Business Executives on What It Takes to Be a Great Leader. He's also been a basketball referee since 1978.You'll discover: The FLIPD model and what the acronym meansHow Billy uses simulations to make learning relevant for learnersThe follow-up components that help leaders ingrain skillsWhat Billy and his team do to help leaders become effective coachesWays that Bill has grown as a leader over the yearsCheck out all the episodesLeave a review on Apple PodcastsConnect with Meredith on LinkedInFollow Meredith on TwitterDownload the free ebook Listen Like a Pro

Messaging can't be one-size-fits-all. Find what you want to communicate to your clients. In this episode of Marketing Mondays, Andreea Borcea interviews David McKie, VP of Life Sciences Marketing of Medidata Solutions at Dassault Systèmes. He speaks of how the acquisition process of Medidata and the aftermath of the COVID-19 pandemic paved the way for how he and his team would approach demand marketing. David explains the strategy that Medidata has taken with customers, talking to them about their challenges and engaging with them before offering them solutions or technology. He talks about virtual versus in-person tools and the importance of customized messaging to have the desired dynamic and pull with the target customers. Finally, he discusses innovation in clinical trials and how he has witnessed large and small companies embrace it differently. Tune in to this episode to learn how David leads demand marketing at Medidata! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Brenda's LinkedIn: https://www.linkedin.com/in/brendamedina1/

Medidata technology has helped to bring COVID-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Decentralised clinical trials, described as the ‘new normal' and the future of clinical research, harness remote technologies to enable patients to participate in clinical trials from their home or preferred location, decreasing patient burden and offering greater flexibility as well as increasing the reach to patients around the world. Lisa Moneymaker is the Senior Vice President of Clinical Operations Technologies for Medidata Solutions. She has over 20 years of pharma, biotech, and medical device industry experience, delivering complex systems solutions in support of excellence in clinical trial execution. Paul O'Donohoe is Senior Director, eCOA Product and Science at Medidata. He is responsible for developing the company's scientific expertise for electronic clinical outcome assessments, and mobile health in clinical trials, and supports internal teams and sponsors around the implementation of industry and regulatory best practices in studies using eCOA. Listen to this podcast to find out more about why decentralised clinical trials are becoming increasingly significant, how the pandemic has affected the clinical trials space, the importance of the patient experience and what clinical trials will look like in the future.

Hottest News Predictions 2021 – Glen de Vries (Billionaire, co-founder of Medidata Solutions and Blue Origin Astronaut ) – What is the mystery about his death in a plane crash? A murder, business, the future of his business… – Clairvoyant/Psychic reading November 25, 2021 – by Clairvoyant House 'Dimitrinka Staikova and daughters Stoyanka and Ivelina Staikova' – from Europe, Bulgaria, Varna http://clairvoyantdimitrinkastaikova.weebly.com https://dimitrinkastaikova.wordpress.com http://clairvoyant-dimitrinka-staikova.my strikingly.com http://sites.google.com/site/dimitrinkastaikova After his space flight with Blue Origin : At October 13,2021 he has a severe pain in his left eye and very sharpened nerve system. There is slight tightening of the muscles at the right shoulder, strong release of acidity in the body. The biocurrents at the front of the body are flowing from left to right. I see a severe Colitis at the large intestine. He had an increased activity in the brain – it is sending biocurrents in huge amounts at the back. There I see the biocurrents are flowing from right to left and they are leaving through the right leg. The top of the head is decreased (painless) and with double circle. The right arm is more painful. The left arm – he is feeling it numb (for a short time). I see two rounds around the Earth. The take-off is the moment that he remembered. There were two moments of take-off – of the rocket and of the astronaut. After the Blue Origin Space flight – I see a research (test) of his physical condition – made by his company. • Payment of money (as from his wallet) to a detective about an investigation of a person. • Threats by a competitive company – related with a contract and Space research. Threats to his relatives (adult woman). Transfer of money from one business into a future space business. And….The Flight of Glen de Vries with a small plane in New Jersey : there was other pilot at the front, Glen de Vries was sitting at the back. At the falling Glen succeeded to release itself and he tried to reach the other pilot. There was one parachute and the pilot gave it to Glen. There was an intentional damage of the plane that lead to the falling. The plane succeeded to stay 2-3 minutes more in the air – it turned to 180 degrees. The other pilot wanted to save Glen de Vries. The killers are connected with the insurance company. His last barely uttered words were : ”Mother” . After the death : attempts and breaking of contracts – Medidata Solutions . At first, the business is divided on two parts, then it will be united again . Without Glen de Vries, this company is turning into a 'Trojan horse' about the business of Blue Origin and Jeff Bezos. Click here to read more : https://dimitrinkastaikova.wordpress.com/2021/11/25/hottest-news-predictions-2021-glendevries-billionaire-co-founder-of-medidatasolutions-and-blueorigin-astronaut-what-is-the-mystery-about-his-death-in-a-planecrash-a-murder-busines/

Tom Doyle, SVP, R&D at Medidata Solutions, sits down with TDS to discuss working with clinical trial software in medical data. Connect with Tom Doyle on LinkedIn The Data Standard is a community of data scientists, architects, engineers, and enthusiasts. In addition to regular podcasts, we host monthly events, publish through leadership pieces, and offer a stimulating ecosystem for networking and collaboration.  https://datastandard.io https://www.linkedin.com/company/the-data-standard https://www.youtube.com/channel/UCTuolowXD05RY9DkIWqRT6Q

Glen de Vries, the 49-year-old co-founder of Medidata Solutions and vice chair at Dassault Systèmes who made headlines when he flew to space with actor William Shatner last month, died in a plane crash in New Jersey on Thursday. This news story got me thinking about the real final frontier. Our Podcast, Blog and YouTube Links https://linktr.ee/rttbros RTTBROS app on Google play https://play.google.com/store/apps/details?id=com.app.rttbros I made an android app for RTTBROS please download it. Best of all it is FREE. Be sure to Like, Share, Follow and subscribe it helps get the word out.

Episode 7 of The Health Conscious Podcast features a conversation with Arnaub Chatterjee of Medidata Solutions on automation and artificial intelligence in the clinical trials industry.

As Head of Healthcare at Unqork, Kara Dennis leads our healthcare go-to-market strategy, owning our efforts with payers, providers, and life sciences companies. Kara joined Unqork from Clarify Health Solutions, an advanced analytics company where she was SVP and GM of Life Sciences. Prior to Clarify, Kara was VP and Managing Director of Mobile Health at Medidata Solutions, a leading cloud provider of clinical trial technologies. Kara also spent several years in the Healthcare practice at McKinsey & Company, and worked at a biotech focused on developing therapies for intensive care units. Through her experience in healthcare technology and clinical trials, Kara has worked with many global healthcare companies to improve clinical trial efficiency and evidence generation, and has deep experience with healthcare workflows and processes. Connect with Kara: https://www.linkedin.com/in/kara-dennis-5109962/ Connect with Poya Osgouei: https://www.linkedin.com/in/poyaosgouei/ Connect with Robby Allen: https://www.linkedin.com/in/robbyallen/ --- Support this podcast: https://anchor.fm/uncharted1/support

David Kocher, VP of Customer Success at Medidata Solutions, shares the segmentation and coverage models he developed so his team can focus on the right customers in the right way. His formula helps prioritize customers using two matrices: ARR mapped against health score and adoption vs. maturity. Resources: Follow David on LinkedInListen to his prediction of the next big wave in Customer SuccessRead David's post on 5 lessons learned from CS change management

Gregory T Simpson has run a marathon in every state, completed the Ironman triathlon, claimed Mount Kilimanjaro, been Chairman of the Board of a $3.5 billion financial institution, and spent the last eight years marketing to the super-smart people in life sciences that make sure all new pharmaceuticals are safe and effective.As the leader of Saama's overall marketing strategy and execution, Greg is responsible for building and strengthening the Saama brand, supporting growth strategies, cultivating opportunities, and increasing demand for Saama solutions.Prior to joining Saama, Greg spent more than five years at Medidata Solutions, a leader in eClinical development software, where he led an integrated marketing team, built a marketing operations team, and oversaw product marketing for the Medidata Clinical Cloud.Before Medidata, he was the Chief Marketing Officer at Frontwave, a cloud software startup. Greg is also the founder of a marketing consultancy and served as the CEO of an internet startup. Prior to those entrepreneurial experiences, he held executive marketing, product management, and sales positions at AT&T.Follow Gregory on LinkedIn here: https://www.linkedin.com/in/gregorytsimpson/Learn more about Saama here: https://www.saama.com/Follow and connect with the host, Connor Dube: https://www.linkedin.com/in/socialsellingexpert/Instagram: connor_dubeIf you're already thinking you need to find a more efficient way to conquer your monthly B2B content like blogs, newsletters, and social media – we'd like to show you how we can improve the quality, save you tons of time, and achieve better results! To learn more visit www.activeblogs.com

Guest: Naveen Bhateja, CHRO, Medidata Solutions Inc. Welcome back to HR Works Podcast’s 5-Minute Fridays. Today I am happy to share a few minutes of my recent interview with Naveen Bhateja, CHRO at Medidata Solutions (https://www.medidata.com/en/) as well as an HR tech advisor, investor, and board director. In this episode, we discuss why HR really should be included on boards of directors, among other things. If you enjoy this segment, consider reading the rest of the interview will be shared on the “Faces of HR” (https://hrdailyadvisor.blr.com/category/faces-of-hr/) column next Thursday, June 3rd. Remember you can always follow us on Twitter at @HRWorksPodcast (https://bit.ly/3l0dzP3), and we are also now available on Spotify (http://spoti.fi/3t8of13) and Audible (http://adbl.co/30uhdaq).

Are you ready to feel inspired to pay it forward? You are invited to take a walk and listen to this interview with Sheryl Chamberlain, Board Chair of Empower (Coupa Women's Program, Director of Alliances Coupa Software and Chair Hult Prize Council. Sheryl shares her insights and experience creating alliances. This conversation with host Natalie Benamou and Sheryl Chamberlain unlocks the power of paying it forward whether we're 18 or 95. How to Get Started with Paying it Forward ● Become an open-ended listener ● Look for ways to bring people together ● Put your hand up and never put it down ● Be open to innovation and new ideas ● Get outside the four walls of your company ● Share best practices ● Be a mentor ● Master the concept that community is the foundation to creating change The Hult Prize ● The Hult Prize foundation brings together students from 3,000 Universities around the world to solve the same problem. ● The 2021 challenge is about food not only insecurity but what it means to change the way we access food. ● This project is an example of the ultimate diversity and inclusion of people from different countries coming together to solve a big problem. Creating an Impact ● Take your experience and share it with someone else. ● “It takes one conversation that can create something that's unbelievable that inspires you each and every day and creates the smile that you want to have in life.”-Sheryl Chamberlain Thank you, Sheryl Chamberlain, for this conversation, your advocacy and starting discussions that create impact and continue to pay it forward. Sheryl Chamberlain In addition to her board roles, Sheryl Chamberlain has earned many industry awards and recognition including Tribute to Women, (TWIN), Women in Technology from Dallas Business Journal, and Global Innovation Partner of the Year from EMC. Sheryl leveraged her broad experience in strategic partnerships, business process improvement, SaaS, enterprise software, program management, business development, and solution selling for companies as diverse as Medidata Solutions, Dell EMC, Capgemini, and The Linux Foundation. Resources mentioned in this episode: Coupa Empower: Creating a Community of Women Program Hult Prize website Hult Prize 2021 Challenge (YouTube video) LinkedIn: Sheryl Chamberlain Website: Innovation Station blog Twitter: Sheryl Chamberlain Natalie Benamou is the CEO of HerPower2 Lead and HerCsuite™ an online platform for transforming the way women meet, engage and thrive together. HerCsuite™ offers women the ability to be surrounded by a personalized curated board of directors inside advisory circles. If you have any questions about this episode, HerPower2 or HerCsuite™ reach out to Natalie at HerCsuite™ This podcast is sponsored by Aaptiv, our favorite health and wellness app with over 4,000 videos. Listeners can get your free 30-day trial here Credits: Thanks to Julie Deem and the Business Podcast Editor for editing our podcast! --- Send in a voice message: https://anchor.fm/hercsuite/message

Are you ready to feel inspired to pay it forward? You are invited to take a walk and listen to this interview with Sheryl Chamberlain, Board Chair of Empower (Coupa Women's Program, Director of Alliances Coupa Software and Chair Hult Prize Council. Sheryl shares her insights and experience creating alliances. This conversation with host Natalie Benamou and Sheryl Chamberlain unlocks the power of paying it forward whether we're 18 or 95. How to Get Started with Paying it Forward ● Become an open-ended listener ● Look for ways to bring people together ● Put your hand up and never put it down ● Be open to innovation and new ideas ● Get outside the four walls of your company ● Share best practices ● Be a mentor ● Master the concept that community is the foundation to creating change The Hult Prize ● The Hult Prize foundation brings together students from 3,000 Universities around the world to solve the same problem. ● The 2021 challenge is about food not only insecurity but what it means to change the way we access food. ● This project is an example of the ultimate diversity and inclusion of people from different countries coming together to solve a big problem. Creating an Impact ● Take your experience and share it with someone else. ● “It takes one conversation that can create something that's unbelievable that inspires you each and every day and creates the smile that you want to have in life.”-Sheryl Chamberlain Thank you, Sheryl Chamberlain, for this conversation, your advocacy and starting discussions that create impact and continue to pay it forward. Sheryl Chamberlain In addition to her board roles, Sheryl Chamberlain has earned many industry awards and recognition including Tribute to Women, (TWIN), Women in Technology from Dallas Business Journal, and Global Innovation Partner of the Year from EMC. Sheryl leveraged her broad experience in strategic partnerships, business process improvement, SaaS, enterprise software, program management, business development, and solution selling for companies as diverse as Medidata Solutions, Dell EMC, Capgemini, and The Linux Foundation. Resources mentioned in this episode: Coupa Empower: Creating a Community of Women Program Hult Prize website Hult Prize 2021 Challenge (YouTube video) LinkedIn: Sheryl Chamberlain Website: Innovation Station blog Twitter: Sheryl Chamberlain Natalie Benamou is the CEO of HerPower2 Lead and HerCsuite™ an online platform for transforming the way women meet, engage and thrive together. HerCsuite™ offers women the ability to be surrounded by a personalized curated board of directors inside advisory circles. If you have any questions about this episode, HerPower2 or HerCsuite™ reach out to Natalie at HerCsuite™ This podcast is sponsored by Aaptiv, our favorite health and wellness app with over 4,000 videos. Listeners can get your free 30-day trial here Credits: Thanks to Julie Deem and the Business Podcast Editor for editing our podcast! --- Send in a voice message: https://anchor.fm/natalie109/message

Dave Bjork is a patient advocate and research evangelist with more than 20 years of progressive experience in nonprofit advocacy, community-building and fundraising leadership roles. He is currently a consultant on the Patient Driven Design team at Medidata Solutions advising on bringing the patient voice to the clinical trial experience. Dave is also host of the Research Evangelist podcast and blog where he interviews people in life sciences that are doing brilliant work in cancer research. Previously Dave served 4 years as Director of Development and Community Relations at FRAXA Research Foundation where he was responsible for building relationships between the Fragile X community and biopharma companies to help advance treatment development in Fragile X syndrome. Before FRAXA Dave spent 4 years as Vice President of Development for National Foundation for Cancer Research where he was responsible for all fundraising and advocacy efforts. A lung cancer survivor, Bjork has made it his life mission to connect patients, biopharma companies, academic institutions and other key influencers to forge strong partnerships to focus on research. He also advocates for and builds bridges between patient groups and the biopharma industry. Bjork earned a BS in Economics and Finance from the Wharton School at the University of Pennsylvania.

In this episode, we have the privilege of hosting the outstanding Arnaub Chatterjee, Senior Vice President of Product and Ecosystem at Acorn AI at Medidata Solutions. Arnaub discusses how his company manages and builds products off of historical clinical trial data to assist the biopharma space. He educates us into the complicated pharma data world, and how the silos between clinical data and real-world data are making it difficult to see and understand the whole patient experience which is crucial in building a better drug. Arnaub also shares some successes, including using a synthetic patient population for phase 3 studies without having actual patients go through a very invasive trial. There are so many things to learn from this amazing interview on clinical trials, AI, and patient data, so please tune in!

Continuous learning is the most valuable currency for career success. Careers no longer follow a simple path from learning to earning to retirement. Lifelong learning is an indispensable skill for every individual and organization. Meet Eileen Schloss, a multidimensional, strategic and transformational human capital expert, who reveals exactly what it takes to get to the C-suite and why continuous learning is the key to success. Eileen recommends managing your life to make sure that you're constantly learning and adapting to change. In this episode, Eileen shares the pivotal moments in her career and how learning and preparation helped her achieve extraordinary success. She provides guidance on positioning for your dream opportunity and how believing in herself and speaking up in her interview with Steve Jobs landed her an executive role at Apple. Eileen also demystifies succession planning and executive compensation; and provides step-by-step guidance on getting board positions. Eileen has worked with CEOs and Boards as a global Chief Human Resources Officer and senior HR leader for companies ranging from major global brands to Pre-IPO businesses needing to scale. She is a Public & Private Board Member, Senior Advisor & Human Capital Expert at Alteryx, Advent and CCC. Visit https://www.iambeyondbarriers.com where you will find show notes and links to all the resources in this episode, including the best way to get in touch with Eileen.   Highlights: [02:41] Eileen’s career journey [04:05] Pivotal moments for career advancement [05:52] Be a continuous learner [08:36] Eileen’s success habits [10:44] Relationships are the key to success [11:38] Eileen’s job interview with Steve Jobs [18:09] How to approach your dream opportunity [19:57] Preparing your presentation in your own voice [22:55] Aligning yourself with succession planning [27:40] Advice on getting to the C-suite [33:58] Demystifying the drivers behind compensation [42:09] Advice to women on negotiating compensation packages [47:23] What to know in positioning yourself for a board role [52:56] Eileen’s advice on accelerating your success   Quotes: “Relationships are a key element of any successful venture.” – Eileen Schloss  “It is important to manage your life around making sure that you're constantly learning.” – Eileen Schloss  “Great leaders are authentic and aren’t afraid to speak up and say what's on their minds.” - Eileen Schloss     About Eileen Schloss: Bold, insightful executive who shapes business and human capital strategy to increase enterprise value for Fortune 500 companies and pre-IPO businesses. Real-world expertise managing acquisitions, divestitures, and change initiatives while steering executive/board compensation decisions for Medidata Solutions, Rovi Corporation, and Apple Computer—crossing industries (health care, technology, media, CPG), business models, and continents (Asia, Europe, North America). In-depth understanding of HR governance and oversight attained through 20+ years as a senior leader and strategist. Keen business acumen strengthened and supported by an astute, thoughtful approach to assessing executive talent and proposing viable, sustainable compensation strategies. Compensation expert and advisor with nearly two decades working directly with board Comp Committees. Joined Alteryx, Inc. public board May 2017, concurrently serving on the Compensation and Nominating/Governance committees. Joined CCC IS, private board August 2020, Chair of the Compensation Committee NACD Board Governance Fellow certification, 2018 - present Links: LinkedIn: https://www.linkedin.com/in/eileen-schloss-executive/  

On the show today, I welcome Glen DeVries, Co-CEO at Medidata, the most used platform for clinical trials worldwide. Not too shabby, I say. Among many other things, we dig into his new book, "The Patient Equation: The Precision Medicine Revolution in the Age of COVID-19". Glen is unique in the annals of woke brainiacs who live in the hyper multi-syllable world of science, data, and related semantic geekery AND YET he is hyperaware that average Jane's and Joe's like you and I prefer to actually understand the words emanating from the mouths of "science people" that may or may not be critical in helping us make life-altering medical decisions. Yes, Glen is The De-Jaronator, says me. He's a controversial and authentic personality. As a bonus, he's also an 80's nostalgia junkie like me, so prepare for some random pop culture references that you may or may not need to IMDB. We also chat about Moore's Law and how it applies to the intersection of biology and technology, how we might need to reframe the concept of an impending robot apocalypse, and whether HAL from 2001: A Space Odyssey could be our future gatekeeper to a clinical trial. This episode moves pretty fast. If you don't stop and listen around once in a while, you could miss our reference to SneakerNet. More at https://www.medidata.com.

The COVID-19 pandemic has left so much disruption to our day to day lives, both personally and professionally.For businesses and organizations, one major struggle that they have to face is maintaining the culture, especially as everybody starts going remote. This episode's guest, Naveen Bhateja, offers his insights and experiences to help you prepare for the future of work, facing the changes in front of us head-on. Naveen is the Chief Human Resources Officer at Medidata Solutions, a technology and software company that is leading the digital transformation of life sciences.Here, he sits down with host, Andy Storch, to share his diverse global experience with us and how it has helped him manage different company cultures at any given time, such as this current pandemic, where people stay connected and engaged. Knowing that there is no existing playbook for a pandemic and the changes we are yet to confront with the current rate we are going, it helps to gather information from the experts to help us rise above the tides. Listen in on this discussion as Naveen guides you to create a progressive organization that is ready to embrace the future of work.

The COVID-19 pandemic has left so much disruption to our day to day lives, both personally and professionally. For businesses and organizations, one major struggle that they have to face is maintaining the culture, especially as everybody starts going remote. This episode's guest, https://www.linkedin.com/in/naveenbhateja/ (Naveen Bhateja), offers his insights and experiences to help you prepare for the future of work, facing the changes in front of us head-on. Naveen is the Chief Human Resources Officer at https://www.medidata.com/en/ (Medidata Solutions), a technology and software company that is leading the digital transformation of life sciences. Here, he sits down with host, Andy Storch, to share his diverse global experience with us and how it has helped him manage different company cultures at any given time, such as this current pandemic, where people stay connected and engaged. Knowing that there is no existing playbook for a pandemic and the changes we are yet to confront with the current rate we are going, it helps to gather information from the experts to help us rise above the tides. Listen in on this discussion as Naveen guides you to create a progressive organization that is ready to embrace the future of work.

The COVID-19 pandemic has left so much disruption to our day to day lives, both personally and professionally. For businesses and organizations, one major struggle that they have to face is maintaining the culture, especially as everybody starts going remote. This episode's guest, Naveen Bhateja, offers his insights and experiences to help you prepare for the […]

For our first episode, we explore the use of AI technology in clinical trials and how the COVID-19 pandemic is promoting the use of advanced technologies within the biopharma industry. This episode is led by our host Karen Taylor. Karen is joined by Fiona Maini, Principal Global Science and Compliance at Medidata, and Fareed Melham, Head of Acorn AI Labs at Medidata Solutions. This episode covers: How AI technology is currently being used in clinical trials How regulators are embracing AI in clinical development How regulators are changing their approach in response to COVID-19, including in the acceptance of AI technologies and RWE strategies.    

Even under COVID-19 quarantine, patients wearing remote sensors keep clinical research moving forward digitally. “Now suddenly, very suddenly, we're faced with an intense patient safety issue where we really are risking patients' lives by having them come into these clinical sites,” explains Paul O’Donohoe, Medidata Solutions. "I suspect we're going to see a significant uptake in the acceptability and use of technology as a way of allowing patients to now provide us that data in the safety of their own homes.” Bill Byrom, Signant Health, moderates this podcast with Paul and Jennifer Goldsack, Digital Medicine Society, and serves on the Steering Committee for the August 2020 virtual Digital Technology in Clinical Trials conference co-sponsored by DIA and the ePRO Consortium of the Critical Path Institute.

Capone leads Qlik’s mission to create a data-literate world, one where people, businesses, organizations and governments tackle their most complex challenges with data. Mike has first-hand experience in leveraging the power of data through analytics to transform businesses and entire industries. In addition to his extensive experience in high-growth SaaS companies, Mike was the COO of Medidata Solutions, a publicly-traded provider of SaaS analytics solutions to the Healthcare, Life Sciences and Pharma markets. There he played a significant role in the company’s product development, data science, professional services and go-to-market operations, accelerating its strategy to provide a comprehensive cloud platform that leverages data and analytics to transform clinical trials. Prior to Medidata, Mike held senior leadership positions at ADP including Corporate Vice President of Product Development, CIO, and SVP & General Manager of ADP’s global outsourcing business. He was also head of product development and technology operations for ADP, one of the world’s largest B2B cloud services providers, delivering critical services to over 600,000 companies and 39 million of their staff members worldwide. Capone holds a bachelor of science degree in computer science from Dickinson College and a master of business administration degree in finance from Pace University.

Join the conversation as Carol Lempert and I discuss networking, having BIG talk, rather than small talk, and how soft skills are actually the HARDER skills - and so necessary!If a psychiatrist and a cute librarian had a love child, it would Carol Lempert. Carol lives and breathes performance. She’s an award winning actress and playwright. (The New York Times has called her a “…resonant performer—with great humor.) She now specializes in helping business executives figure out what to say during high stakes—or ‘spot light’ moments—and how to say it.Carol is a sought after expert and has been quoted in Forbes, Reader’s Digest, the Financial Post and the Detroit Free Press. Clients include: Google, American Express, University of Michigan Ross School of Business, AT Kearney, Medidata Solutions, Beckman Coulter, Sciex, Danaher, and Harvard School of Business (yes THAT Harvard. Her mother is too proud.)Her most popular programs are: •Get Seen. Be Heard. Unlock Your Presence•Own Your Brand—Before It Owns You•Stories that Sell•Take the Guessworking out of Networking•No More Death By PowerPoint•Sabotage: The 7 mistakes Career Women MakeCarol received her Masters degree in Communication and Performance from York University. She lives with her husband; the comedian and improv master Scotty Watson, in a cozy home near the Hackensack River and has been known to eat Haagen Dazs ice cream for breakfast.www.CarolLempert.comemail: Info@CarolLempert.comhttps://www.linkedin.com/in/carollempert/https://www.facebook.com/CarolLempertSpeaking/On Twitter: @CarolLempertwww.mhnrnetwork.com

Join the conversation as Carol Lempert and I discuss leadership, and how to support your team (and yourself!) during the holidays.If a psychiatrist and a cute librarian had a love child, it would Carol Lempert. Carol lives and breathes performance. She’s an award winning actress and playwright. (The New York Times has called her a “…resonant performer—with great humor.) She now specializes in helping business executives figure out what to say during high stakes—or ‘spot light’ moments—and how to say it.Carol is a sought after expert and has been quoted in Forbes, Reader’s Digest, the Financial Post and the Detroit Free Press. Clients include: Google, American Express, University of Michigan Ross School of Business, AT Kearney, Medidata Solutions, Beckman Coulter, Sciex, Danaher, and Harvard School of Business (yes THAT Harvard. Her mother is too proud.)Her most popular programs are: •Get Seen. Be Heard. Unlock Your Presence•Own Your Brand—Before It Owns You•Stories that Sell•Take the Guessworking out of Networking•No More Death By PowerPoint•Sabotage: The 7 mistakes Career Women MakeCarol received her Masters degree in Communication and Performance from York University. She lives with her husband; the comedian and improv master Scotty Watson, in a cozy home near the Hackensack River and has been known to eat Haagen Dazs ice cream for breakfast.www.CarolLempert.comemail: Info@CarolLempert.comhttps://www.linkedin.com/in/carollempert/https://www.facebook.com/CarolLempertSpeaking/On Twitter: @CarolLempertwww.mhnrnetwork.com

Glen is the President and Co-founder of Medidata Solutions, the leading cloud platform for life sciences research. Glen has been driving Medidata's mission since the company's inception in 1999: Powering smarter treatments and healthier people. His publications have appeared in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, STAT, Urologic Clinics of North America and TechCrunch. He is a trustee of Carnegie Mellon University, a Columbia HITLAB Fellow, and a member of the Healthcare Businesswomen's Association European Advisory Board.

In this podcast from the 2018 Mobile in Clinical Trials conference, Mohammad Ali, Global Head Digital Trials- Global Clinical Operations, Boehringer-Ingelhiem and Joe Dustin, Principal, Mobile Health, Medidata Solutions discussed the internal infrastructure that is required for the successful scaling of mobile/digital tools in clinical trials. The discussion focuses on how to come to terms with the demand of data, understanding the skill set required to purposefully use the data and implementing an internal system to allow for efficient scaling of mobile trials.? Mohammad Ali is returning to Mobile 2019 to lead an interactive group activity on creating a pathway for brainstorming the digital biomarker process. Speakers: Mohammad Ali, Global Head Digital Trials- Global Clinical Operations, Boehringer-Ingelhiem                   Joe Dustin, Principal, Mobile Health, Medidata Solutions                  

This week we bring you our second installment of the 26th Annual IPLJ Symposium, “Data Governance Regimes Panel.” Moderated by Olivier Sylvain, Professor of Law at Fordham University of Law, The Data Governance Regimes panel will discuss the challenges in maintaining the privacy and confidentiality of data as it continues to accumulate. Panelists will evaluate current compliance obligations and the effectiveness of the FTC in providing standardized frameworks for effective governance, depending on the type of data that companies collect. Panelists will review recommendations for and against more expansive federal and state privacy legislation, looking at whether current regulations support modern business models and innovation in the digital sphere. Panelists include: Lisa J. Sotto, Partner and Chair, Privacy and Cybersecurity Practice at Hunton Andrews Kurth LLP; Boris Segalis, Partner and Global Vice Chair, Cyber/Data/Privacy at Cooley LLP; Andrew Kopelman, Vice President, Assistant General Counsel, and Chief Privacy Counsel at Medidata Solutions; Anthony Ford, Senior Data Privacy Counsel at Medidata Solutions. Our theme song is Roller Blades by Otis McDonald. Subscribe to us on Apple Podcasts and leave us a review! Website: www.fordhamiplj.org Twitter: @FordhamIPLJ Instagram: @Fordhamiplj Facebook: www.facebook.com/FordhamIPLJ Patreon: www.patreon.com/fordhamiplj

This week Shira talks with Joshua Pines, an American who lives in London. They talk about how Joshua is using partners to grow his SaaS company. Joshua Pines has spent nearly 20 years on the business side of the technology industry. He is a co-founder and the head of corporate development and marketing for Sirenum, a workforce management SaaS platform based in North London. Previously, Josh was a marketing executive at Medidata Solutions, the leading provider of cloud-based technology to the life sciences. He has also held marketing, product, and strategy leadership roles for organizations such as IBM, Gerson Lehrman Group, and JFL Media. As well, he has been a management consultant with both Deloitte Consulting and PricewaterhouseCoopers Consulting, focused on strategy, technology, and new product innovation. A published photographer and frequent public speaker, Josh also regularly consults with investment firms on their technology investments. He holds a BA from Brandeis University and an MBA from the University of Miami. A South Florida native, Josh is an avid cook and likes to play basketball and travel with his family. He is co-president of the Brandeis University Alumni Club of Great Britain and is a member of the board of Shomrei Hadath Synagogue in West Hampstead, where he lives with his wife and twin daughters. If you like SaaS Insider - please leave us a comment.

A panel of executives from leading pharma and the venture capital community at the DPharm Disruptive Innovations conference recently awarded the 2013 Disruptive Innovator of the Year title to Medidata Solutions and Spaulding Clinical Research. They won for their collaboration on a novel study evaluating the impact of mobile and cloud-based technology on patient engagement for improved health outcomes in the diabetes community. Host Craig Lipset, Head of Clinical Innovation, R&D at Pfizer speaks with Dr. Andrew Lee of Sanofi on key takeaways from the 2013 DPharm conference along with the CEOs of  the winning companies to learn more about their collaboration. Guests: Andrew Lee, MD, SVP, Deputy Head of Clinical Sciences & Operations, Sanofi Glen De Vries, President of Medidata Solutions Randy Spaulding, Founder and CEO of Spaulding Clinical Research